Type of information: Grant
Company: RoslinCT (UK) Reprocell (UK)
Investors: Innovate UK (UK)
Amount: £1.2 million
Funding type: grant
- Funding will be used to improve efficiency of induced pluripotent stem cell production. RoslinCT and Reprocell will develop an innovative strategy for the production of clinical iPSCs, by using a novel, safe RNA-based reprogramming method. This will enable quicker and safer generation of cells for both allogeneic and autologous therapies, and provide scope for commercialisation and licensing of the generated cell lines to the biotechnology sector.
- The iPSCs will provide a suitable starting material for a number of advanced therapy medicinal products (ATMPs) that offer ground breaking opportunities for the treatment of life-changing and life-threatening disease and injury, including those where patients’ needs are currently unmet. Bringing together the expertise of RoslinCT and Reprocell will provide a step change in the production of clinical grade iPSCs and centre the know-how and manufacturing within the UK.
- • On October 10, 2018, RoslinCT, a cell and gene therapy contract manufacturing organisation, announced it is to receive a £1.2 million investment to collaborate with Reprocell Europe , a UK-based stem cell company, on a project which will develop a faster, more cost-effective method of producing clinical-grade induced pluripotent stem cells (iPSCs). The investment comes from Innovate UK’s Medicines Manufacturing Round 2 competition, as part of the UK Government investment strategy in developing technology to transform health and social care.
Therapeutic area: Technology - Services